Transgene and NEC Bio Advance TG4050 Development
Transgene S.A., a biotechnology company based in Strasbourg, France, and NEC Bio B.V., a subsidiary of NEC Corporation, signed a license agreement on April 2, 2026, to pursue clinical development of TG4050, a personalized neoantigen vaccine for adjuvant treatment of HPV-negative head and neck cancer after surgery, according to GlobeNewswire PE. TG4050 uses a Modified Vaccinia Ankara viral vector to target neoantigens selected via NEC’s AI-based prediction platform.
Details of the License Agreement
The agreement grants Transgene access to NEC’s AI platform for predicting neoantigens to continue developing TG4050 specifically for HPV-negative head and neck cancer post-surgery. NEC retains full ownership and operational control of its AI platform while supporting Transgene in subsequent clinical activities. Under the terms, NEC will receive 2.5 million euros in Transgene shares upon signing and an additional 2.5 million euros in cash paid in tranches until the beginning of 2028.
Technology and Clinical Focus
TG4050 is designed to stimulate the immune system by targeting tumor-specific genetic mutations, with neoantigens selected using NEC’s machine learning-based platform that identifies immunogenic mutations likely to induce strong immune responses. The vaccine is currently being evaluated in patients with head and neck cancer to prevent disease relapse and extend disease-free survival after surgery and adjuvant treatment, according to GlobeNewswire PE. As context, biotechnology firms often collaborate on AI-driven tools for personalized medicine, though this deal specifically involves viral vector-based immunotherapies.
Financial and Partnership Aspects
The license also provides Transgene with rights for further clinical development, commercialization, and potential partnerships for TG4050, while NEC may receive additional milestone-based payments, some in Transgene shares, and other development-related payments whose amounts are confidential. NEC is positioned as a leader in IT, networks, and AI technologies, supporting this collaboration through its platform.
